GALOMIC
LIVE

Serial Number

97855624

Owner

E-Therapeutics Plc

Attorney

Anna King

Filing Date

Mar 24, 2023

Add to watchlist:

No watchlists yet
View on USPTO

GALOMIC Trademark

Serial Number: 97855624 • Registration: 7575494

GALOMIC is a trademark filed by E-Therapeutics Plc on March 24, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

E-Therapeutics Plc (13 trademarks)

Oxfordshire OX298LN , GB

Entity Type: 99

TANGRAM THERAPEUTICS PLC

4 KINGDOM STREET
LONDON W2 6BD , GB

Entity Type: 84

Trademark Details

Filing Date

March 24, 2023

Registration Date

November 26, 2024

Published for Opposition

October 3, 2023

Goods & Services

Scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking gene expression, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and, pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; scientific and technical data analysis in relation to pharmaceuticals and medicines; scientific and technical data analysis in relation to RNAi-based medicines; scientific and technical data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific and technical data analysis in relation to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design, development, creation and maintenance of computer platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer platforms and computer software enabling the searching and retrieval of data relating to pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer platforms and computer software for the analysis of data relating to pharmaceuticals, medicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for use in the field of pharmaceuticals, medicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for the searching, retrieval, indexing and analysis of data relating to pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations all for use in the fields of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation, all for use in the fields of pharmaceuticals, medicines, and drug discovery; design and development of computer-simulated models for use in the field of pharmaceuticals, medicines and drug discovery; providing temporary use of online non-downloadable computer software for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations, all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software for facilitating the targeted delivery of pharmaceutical and medical preparations, all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software for facilitating the targeted delivery of pharmaceutical and medical preparations for silencing or inhibiting gene expression, all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software for facilitating the targeted delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer for machine learning for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software using artificial intelligence for machine learning for facilitating the delivery of pharmaceutical and medical preparations, all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software using artificial intelligence for machine learning for facilitating the delivery of pharmaceutical and medical preparations targeting genes and silencing or inhibiting gene expression, all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software using artificial intelligence for machine learning for facilitating the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software using artificial intelligence for machine learning for facilitating the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for targeting genes and silencing or inhibiting gene expression, all for use in the field of pharmaceuticals, medicines and drug delivery; Software as a Service (SaaS) services featuring software using artificial intelligence and machine learning software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations databases all in the field of pharmaceuticals, medicines and drug discovery; Software as a Service (SaaS) services featuring software using artificial intelligence and machine learning for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation, all for use in the fields of pharmaceuticals, medicines and drug discovery; provision of information, advice and consultancy services relating to all of the aforesaid

Downloadable and recorded computer software for use in the field of pharmaceuticals, medicines and drug delivery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software for facilitating the targeted delivery of pharmaceutical and medical preparations; downloadable and recorded computer software for facilitating the targeted delivery of pharmaceutical and medical preparations for silencing or inhibiting gene expression; downloadable and recorded computer software for facilitating the targeted delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs); downloadable and recorded computer software using artificial intelligence for machine learning for use in the field of pharmaceuticals, medicines and drug delivery; downloadable and recorded software using artificial intelligence for machine learning for facilitating the delivery of pharmaceutical and medical preparations; downloadable and recorded software using artificial intelligence for machine learning for facilitating the delivery of pharmaceutical and medical preparations targeting genes and silencing or inhibiting gene expression; downloadable and recorded software using artificial intelligence for machine learning for facilitating the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs); downloadable and recorded software using artificial intelligence for machine learning for facilitating the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for targeting genes and silencing or inhibiting gene expression; electronic databases for use in the field of pharmaceuticals, medicines and drug delivery recorded on computer media; electronic databases for use in the field of gene therapy recorded on computer media; electronic databases for use in the field of gene therapy, namely, the delivery of pharmaceutical and medical preparations recorded on computer media; electronic databases for use in the field of gene therapy, namely, the delivery of pharmaceutical and medical preparations targeting and silencing or inhibiting of genes recorded on computer media; electronic databases for use in the field of gene therapy, namely, the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs) recorded on computer media; downloadable and recorded computer platform software for use in the field of pharmaceuticals, medicines and drug delivery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software platforms for use in the field of pharmaceuticals, medicines and drug delivery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software for enabling the searching and retrieval of data relating to pharmaceuticals, medicines and drug discovery; downloadable and recorded software for the analysis of data relating to pharmaceuticals, medicines and drug discovery; downloadable and recorded search engine software for use in the field of pharmaceuticals, medicines and drug discovery; downloadable and recorded search engine software for the searching, retrieval, indexing and analysis of data relating to pharmaceuticals, medicines and drug discovery

Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of pharmaceutical preparations targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs); drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; short interfering RNA-based (siRNA) medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation

Custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid

Filing History

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jun 10, 2026 ASGN
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 26, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Nov 26, 2024 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Nov 5, 2024 DP1B
NOTICE OF ALLOWANCE CANCELLED
Nov 4, 2024 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Nov 4, 2024 D1BR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 30, 2024 EXRA
SOU EXTENSION 1 GRANTED
Apr 29, 2024 EX1G
SOU EXTENSION 1 FILED
Apr 29, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 29, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 28, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 3, 2023 NPUB
PUBLISHED FOR OPPOSITION
Oct 3, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 13, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 31, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 29, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 29, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 29, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 29, 2023 CNEA
TEAS VOLUNTARY AMENDMENT RECEIVED
Aug 1, 2023 PARI
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 24, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 24, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 24, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 27, 2023 GNRN
NON-FINAL ACTION E-MAILED
Apr 27, 2023 GNRT
NON-FINAL ACTION WRITTEN
Apr 27, 2023 CNRT
ASSIGNED TO EXAMINER
Apr 25, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 16, 2023 NWOS
NEW APPLICATION ENTERED
Mar 28, 2023 NWAP